Hypercapnic respiratory failure  by Zakynthinos, S. & Roussos, C.
Respiratory Medicine (1993) 87,409-411 
Hypercapnic respiratory failure 
Hypercapnia, i.e. elevation of arterial PCO, 
(PaCO,) greater than 45 mmHg, is a usual clinical 
condition and remains an interesting topic, mainly in 
terms of its pathophysiology. It can be present either 
acutely or insidiously. Although in every particular 
disease hypercapnia ensues through various pathways, 
the most common feature of hypercapnic respiratory 
failure is the reduction in tidal volume (VT). Thus, 
an increase of the ratio of dead space (VD) over VT 
(vD/ VT) by decreasing VT is a general characteristic 
of respiratory failure, leading to hypercapnia. However, 
decreased minute ventilation ( LE) and/or increased 
CO, production may contribute to the elevation of 
PaCO,. 
In asthma and exacerbations of COPD, which are 
common causes of acute hypercapnic respiratory fail- 
ure, severe airway obstruction results in reduction of 
dynamic compliance and in rapid, shallow breathing. 
These factors increase the work of breathing and the 
energy demand, leading to breathlessness and poten- 
tially, to fatigue. The latter is a very probable hazard, 
as hyperinflation to achieve adequate gas exchange can 
be severe; the strength and efficiency of muscles under 
these conditions are reduced. At the same time the 
required pressure per breath (Ptidal) is increased 
excessively due to auto-PEEP, high elastic and resis- 
tive inspiratory load. Hyperinflation predisposes 
maximum inspiratory pressure (Pmax) to decrease and 
hence, Ptidal/Pmax to increase, leading potentially 
to fatigue. Such a situation forces into alveolar hypo- 
ventilation by reducing tidal volume, either as a pro- 
tective mechanism for the muscles or as a consequence 
of failure (fatigue) of the muscles. It must be noted 
that, because of hyperinflation, values of Ptidal/ 
Pmax lower than that needed in FRC, i.e. about 0.50 
(1) are adequate to lead the inspiratory muscles to 
fatigue. 
In most neuromuscular diseases with acute onset 
(e.g. diaphragmatic paralysis, poisons such as organo- 
phosphates), weakness of the respiratory muscles is a 
very common feature that leads to ventilatory failure. 
In such conditions, the remaining normal muscle cells 
cannot develop sufficient force to maintain adequate 
alveolar ventilation and hypercapnia ensues. This may 
be the result of central nervous system adaptation, 
muscle fatigue or both. It is apparent that the clinical 
expression of failure (acute vs. chronic) depends on the 
nature of the underlying disease. It may vary from 
rapid onset, as in Guillain-Barre syndrome, to stable 
chronic failure, as in long standing poliomyelitis. The 
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latter group is extremely vulnerable to acute failure 
compounding their chronic failure under a variety of 
conditions (e.g. infection, increased CO, production, 
sedation, anaesthesia, surgery). 
In cardiogenic shock there is an increase in energy 
demand (stiff lungs, hyperventilation) and a decrease 
in the supply of blood to respiratory muscles. In such a 
disease state, the respiratory muscles may fail. The 
condition is well described in animal models; respirat- 
ory muscle fatigue leads to severe alveolar hypoventi- 
lation and is followed by bradypnoea and respiratory 
arrest (2). Early mechanical ventilation prevents this 
from occurring; blood flow is redirected from respir- 
atory muscles and diverted to vital organs, while 
lactate production is minimized (3). In non-cardiogenic 
pulmonary oedema, patients need increased pressure 
and energy to ventilate the lungs. Coexisting severe 
hypoxaemia due to lung damage may diminish the 
energy supply to the muscles; furthermore, weakness 
of the respiratory muscles may be present as a result 
of malnutrition or sepsis. This imbalance between 
capacity of the ventilatory pump and demands made 
upon it leads again to alveolar hypoventilation. 
In all the above causes of acute hypercapnia, the 
mechanisms responsible for CO, retention are both 
decreasing minute ventilation and increasing in VD/ 
VT. The sequence of events and their potential expla- 
nation is as follows: The patients with weak and/or 
loaded respiratory muscles by decreasing inspiratory 
time (7-Q reduce tidal volume in order to diminish 
Ptidal and the energy demand per breath (expressed by 
the pressure - time index, PTI). In addition, with this 
strategy the respiratory muscles operate at an optimal 
length and will not substantially affect their geometry, 
since large tidal breaths force the muscles to shorten 
more than the small tidal breaths. This reduction in VT 
is compensated at least at the beginning by increasing 
breathing frequency so that minute ventilation is 
maintained or increased. In consequence, since such a 
pattern of. breathing increases VD/VT, PaCO, .will 
increase if VE is preserved, or may remain stable if VE is 
increased proportionately. Such a frequency of breath- 
ing, however, is no longer optimal and for the same 
alveolar ventilation the energy demand will increase. 
Thus, although the non optimal frequency seems to 
be a better option than the long n, coupled with the 
inadequate energy supply will finally lead to muscle 
fatigue. Pressure will then decrease and as a result VT 
and VE will decrease while VD/VT further increases. 
The reduction in pressure will obviously decrease the 
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PTiand energy demands per breath, but alveolar ven- 
tilation (k~) will be further reduced and PaCO, will 
rise. At a later stage (for example in patients during 
weaning failure or in animal models with shock) via 
central mechanisms, Tr increases again and respiratory 
frequency gradually decreases, resulting in drop of VE 
(2,4). Finally, at extreme fatigue, the central nervous 
system reduces the output signals per breath, further 
reducing tidal pressure and VT, eventually leading to 
respiratory arrest. 
Patients who retain CO, insidiously invariably need 
to generate high pressure per breath that is a large 
fraction of their maximum inspiratory pressure. The 
pressure is generated to overcome forces imposed by 
the chest wall (kyphoscoliosis, thoracoplasty, pleural 
thickening, severe obesity), by the lung (bronchitis, 
emphysema, bronchiectasis) or by both (scleroderma, 
polymyositis). In a category of patients, although 
Ptidal is normal it may be a large fraction of Pmax, 
since the latter is reduced (neuromuscular disorders). 
It is difficult to ascertain the mechanism of CO, reten- 
tion in such patients. However, reduction of VT is a 
frequent feature and, therefore, may be the common 
pathway to CO, retention by increasing in VD/VT. 
Two alternative pathways are proposed, which are 
not mutually exclusive. As disease progresses, the 
pressure, PTZ, or power required to maintain adequate 
ventilation, is increased and the muscles become more 
vulnerable to dyspnoea and fatigue. In this process, 
the central nervous system may set a lower level of 
ventilation or may alter the pattern of breathing in 
order to avoid dyspnoea or exhaustion. Alternatively, 
it is possible that the ventilatory pump becomes 
chronically fatigued (centrally or peripherally), so 
decreases in alveolar ventilation are the result of pump 
failure. Both mechanisms may be operative. 
When COPD patients who retained CO, were 
compared to those who did not retain CO,, it was 
found that VT and 2-1 were reduced in the CO, 
retainers, while frequency was increased (5). At equal 
minute ventilation, VD/VT was higher in the CO, 
retainers and hence, CO, increased. The increased VD/ 
VT may be explained as follows: Patients who retain 
CO, have lower forced expiratory volume in 1 s (FEV,) 
and Pmax values, higher effective impedances, and 
higher weights, functional residual capacities (FRCs), 
and FRC/total lung capacity (TLC) ratios than do non 
retainers of CO, (5,6). At equal driving force (PO.,), 
such a patient is better off terminating Tr early, thus 
avoiding substantial deviation from optimal length 
and perhaps, avoiding substantial geometric alter- 
ations of the diaphragm and intercostal muscles than 
by taking a large VT (long 7’1). In the latter case, at the 
end of inspiration, this type of patient may have to 
develop pressure that approaches or exceeds the ‘criti- 
cal’ inspiratory pressure, leading to severe dyspnoea or 
fatigue. In fact, although hypercapnia can be reduced 
in COPD patients by voluntarily changing the breath- 
ing pattern, i.e. increasing VT and decreasing fre- 
quency, it has been shown that this type of breathing 
brings about fatigue of the inspiratory muscles and 
that the imposed pattern cannot be tolerated more 
than a few minutes (7). In this regard, patients with 
COPD and CO, retention developed a mean tidal 
inspiratory pressure (Ptidal) that was 27% of Pmax, 
whereas the Ptidal in patients with no CO, retention 
was only 10% of Pmax (6). Using the results from 
normal subjects in which the critical pleural pressure 
for developing fatigue at FRC plus one half inspira- 
tory capacity is 2530% of the maximum (1), we may 
place the CO, retainers above or in the critical zone 
of fatigue, whereas non retainers remain in the non 
fatiguing zone. In patients with COPD and PaCO, less 
than 45 mmHg, this was especially evident. The Ptidal/ 
Pmax was 10% and the residual volume (RV)/TLC 
ratio 50% (6); that is, the tidal inspiratory pressure was 
certainly below the critical zone for developing fatigue. 
In contrast, in patients whose RV/TLC was 67% and 
who retained CO,, Ptidal/Pmax was 27% (6) - a value 
highly probable to predispose the muscles to fatigue. 
Thus, in some patients the combination of increased 
work of breathing due to lung disease and/or obesity, 
decreased mechanical efficiency due to hyperinflation 
and/or airway resistance, and muscle weakness due to 
hyperinflation and/or atrophy and under-nutrition, 
pushes the respiratory muscle to the limits. In such a 
predicament, there are two alternative pathways. First, 
the central controllers (via a feedback mechanism) 
reduce the n and VT and hence, the Ptidal. Thus 
fatigue is avoided. If it is so, hypercapnic subjects 
behave as ‘wise fighters’ who weigh their options and 
choose hypoventilation rather than respiratory muscle 
fatigue (6). Second, the muscles pass into a stage of 
chronic failure (fatigue), leading to reduction in the 
driving pressure and VT. However, this proposition 
has not as yet been tested. 
Respiratory muscle afferents seem to play an im- 
portant role in choosing the frequency or duty cycle of 
breathing. All authors agree that the supraspinal pro- 
jections of small fibres (types III and IV) of phrenic 
afferents have aneffect on the control of breathing. These 
sensory fibres are activated primarily by extracellular 
metabolic changes [e.g. low pH, ischaemia, increased 
osmolarity and some substances (phenyl-diguanide, 
capsaicin)]. In addition, endogenous opioids have been 
widely implicated in the response to prolonged stress 
such as shock, hypoxia combined with acidosis, or 
progressive exercise to exhaustion. Edelman and his 
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colleagues have shown that in both patients and 
animals breathing against a heavy load, or under 
conditions of brain hypoxia, endogenous opioids alter 
the central controllers significantly while naloxone 
prevents or reverses this effect (8,9). In fact, they 
showed that the administration of the opioid antagon- 
ist naloxone restored respiratory compensation for a 
flow-resistive load in those patients with chronic 
obstructive pulmonary disease in whom it was found 
to be absent and also resulted in significant increases 
in tidal volume in awake goats breathing against 
resistive loads applied for short periods of time. Thus, 
we speculate that afferents from the small fibres 
(type III and IV) stimulated by the heavy work (ergo- 
receptors, type III) or by noxious substances like 
lactic acid (nociceptors, type IV) modify the central 
nervous system output by modulating endogenous 
opioids as an adaptive response (10). This strategy 
obviously minimizes breathlessness and protects the 
ventilatory pump from fatigue and exhaustion, which 
undoubtedly is a very terminal event. However, the 
decrease in VT reduces alveolar ventilation and CO, 
levels rise. 
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